Therapeutic Area Market Research Reports & Industry Analysis
Therapeutic areas include Cardiology/Vascular Diseases, Dental and Oral Health, Dermatology, Devices, Endocrinology, Family Medicine, Gastroenterology, Genetic Disease, Healthy Volunteers, Hematology, Hepatology, Immunology, Infections and Infectious Diseases, Internal Medicine, Musculoskeletal, Nephrology, Neurology, Nutrition and Weight Loss, Obstetrics/Gynecology, Oncology, Ophthalmology, Orthopedics/Orthopedic Surgery, Otolaryngology, Pediatrics/Neonatology, Pharmacology/Toxicology, Podiatry, Psychiatry/Psychology, Pulmonary/Respiratory Diseases, Rheumatology, Sleep, Trauma, Urology, and Vaccines.
Reports in these categories will contain statistics of prevalence and growth concerning therapeutic area diseases for which there are product reviews, market size, and share for products that are used in pharmaceutical treatment or equipment that used in surgical treatment of the therapeutic area.
Therapeutic Area Industry Research & Market Reports
-
In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2025-2033
... The growing prevalence of chronic diseases worldwide and the increasing R&D expenditure by pharmaceutical companies are propelling the market growth. In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual ... Read More
-
Artificial Insemination
... CAGR of 7.2% over the analysis period 2024-2030. Intrauterine Insemination, one of the segments analyzed in the report, is expected to record a 7.7% CAGR and reach US$2.8 Billion by the end of the analysis ... Read More
-
Assisted Reproductive Technology
... at a CAGR of 4.9% over the analysis period 2024-2030. In-Vitro Fertilization (IVF), one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$22.0 Billion by the end ... Read More
-
Benign Prostatic Hyperplasia Devices
... 2030, growing at a CAGR of 5.0% over the analysis period 2024-2030. TURP, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$389.8 Million by the end ... Read More
-
Bovine Respiratory Disease Treatment
... 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.4 Billion by the end ... Read More
-
Brain Health Supplements
... at a CAGR of 5.4% over the analysis period 2024-2030. Natural Molecules, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$6.8 Billion by the end of ... Read More
-
Breast Lesion Localization
... at a CAGR of 4.5% over the analysis period 2024-2030. Breast Biopsy, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$309.2 Million by the end of ... Read More
-
Breast Implants
... CAGR of 6.0% over the analysis period 2024-2030. Silicone Implants, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$4.2 Billion by the end of the analysis ... Read More
-
Cancer Diagnostics
... CAGR of 5.8% over the analysis period 2024-2030. Imaging, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$95.3 Billion by the end of the analysis period. ... Read More
-
Chemotherapy-induced Nausea and Vomiting Drugs
... Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Serotonin Receptor Antagonist, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.0 ... Read More
-
Heart Failure Drugs
... at a CAGR of 12.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 16.3% CAGR The Heart Failure Drugs market in the U.S. ... Read More
-
Critical Care Therapeutics
... at a CAGR of 5.7% over the analysis period 2024-2030. Albumin, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$3.7 Billion by the end of the ... Read More
-
Digestive Enzyme Supplements
... at a CAGR of 5.8% over the analysis period 2024-2030. Animal Source, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$817.7 Million by the end of ... Read More
-
Preimplantation Genetic Diagnosis (PGD)
... 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Chromosomal Abnormalities, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$33.6 Million by the ... Read More
-
Respiratory Diagnostics
... CAGR of 4.5% over the analysis period 2024-2030. Instruments & Devices, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$5.1 Billion by the end of the ... Read More
-
Anticoagulants
... 9.2% over the analysis period 2024-2030. NOACs, one of the segments analyzed in the report, is expected to record a 10.8% CAGR and reach US$33.4 Billion by the end of the analysis period. Growth in ... Read More
-
Fertility Testing
... CAGR of 6.3% over the analysis period 2024-2030. Ovulation Predictor Kits, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$571.1 Million by the end of the ... Read More
-
Infertility Drugs
... CAGR of 5.2% over the analysis period 2024-2030. Hormone-Based Therapy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$5.3 Billion by the end of the analysis ... Read More
-
Invisible Orthodontics
... CAGR of 9.2% over the analysis period 2024-2030. Clear Aligners, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach US$5.5 Billion by the end of the analysis ... Read More
-
Kidney Function Tests
... at a CAGR of 4.9% over the analysis period 2024-2030. Dipsticks, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$765.0 Million by the end of the ... Read More
-
NDDS in Cancer Therapy
... 2030, growing at a CAGR of 20.7% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 20.6% CAGR and reach US$67.8 Billion by the end ... Read More
-
Endometrial Ablation Devices
... at a CAGR of 5.6% over the analysis period 2024-2030. Radiofrequency Ablation, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$628.5 Million by the end of ... Read More
-
Vitiligo Therapeutics
... CAGR of 4.0% over the analysis period 2024-2030. Topical, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$1.2 Billion by the end of the analysis period. ... Read More
-
Women`s Health Diagnostics
... at a CAGR of 5.8% over the analysis period 2024-2030. Breast Cancer Testing, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$11.3 Billion by the end ... Read More
-
Dilated Cardiomyopathy Therapeutics
... at a CAGR of 4.3% over the analysis period 2024-2030. Angiotensin II Receptor Blockers (ARBs), one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$258.2 Million by ... Read More
Research Assistance
